‘Pasithea Therapeutics Corp. Adjourns Annual Meeting to Allow Stockholders Additional Time to Vote on Proposals\n\nSOUTH SAN FRANCISCO, Calif. And MIAMI, November 29, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (“The company”) (NASDAQ:KTTA) has announced that its annual meeting of stockholders, originally scheduled for November 29, 2023, has been adjourned to December 19, 2023 at 9:00 a.m. Eastern Time. The adjournment is to provide stockholders additional time to vote on the proposals described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (“SEC”) on October 26, 2023.\n\nThe original record date of October 12, 2023 remains the same for the adjourned Annual Meeting. Stockholders of record may attend the virtual webcast meeting by logging in through the same method as set forth in the Company’s Proxy Statement. The Company’s board of directors believes approval of each of these proposals is in the best interests of the Company and its stockholders.\n\nPasithea is a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. The company has an experienced team of experts in the fields of neuroscience, translational medicine, and drug development. They are currently developing new molecular entities for the treatment of neurological disorders, including Amyotrophic Lateral Sclerosis (ALS), Neurofibromatosis type 1 (NF1), Noonan syndrome, and Solid Tumors.\n\nThis press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include all statements, other than statements of historical fact, regarding the Company’s current views and assumptions with respect to future events regarding its business, the success of the Company’s current and future business strategies, product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities, and other statements that are predictive in nature.\n\nForward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including factors set forth in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings made with the SEC. Thus, actual results could be materially different.\n\nIn a Pasithea Therapeutics Corp. has adjourned its Annual Meeting to allow stockholders additional time to vote on proposals. The company believes that approval of these proposals is in the best interests of the company and its stockholders. Pasithea is a biotechnology company focused on developing innovative treatments for CNS disorders and RASopathies.’